GlaxoSmithKline PLC Director/PDMR Shareholding (7360T)
17 October 2017 - 2:40AM
UK Regulatory
TIDMGSK
RNS Number : 7360T
GlaxoSmithKline PLC
16 October 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Ms E Walmsley
=== ======================== ================================================
b) Position/status Chief Executive Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.2750 1,605.036
------------ ----------
GBP15.2750 831.931
------------ ----------
GBP15.2750 2,740.030
------------ ----------
GBP15.2750 4,439.830
------------ ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
9,616.827
GBP15.2750
=== ======================== ================================================
e) Date of the transaction 2017-10-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr R G Connor
=== ======================== ================================================
b) Position/status President, Global Manufacturing & Supply
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.2750 1,249.200
------------ ----------
GBP15.2750 1,600.015
------------ ----------
GBP15.2750 1,529.167
------------ ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
4,378.382
GBP15.2750
=== ======================== ================================================
e) Date of the transaction 2017-10-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr L Debruyne
=== ======================== ================================================
b) Position/status President, Global Vaccines
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.2750 319.540
------------ ----------
GBP15.2750 402.745
------------ ----------
GBP15.2750 1,147.102
------------ ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
1,869.387
GBP15.2750
=== ======================== ================================================
e) Date of the transaction 2017-10-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr S Dingemans
=== ======================== ================================================
b) Position/status Chief Financial Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.2750 2,716.836
------------ ----------
GBP15.2750 2,942.442
------------ ----------
GBP15.2750 2,427.360
------------ ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
8,086.638
GBP15.2750
=== ======================== ================================================
e) Date of the transaction 2017-10-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr N Hirons
=== ======================== ================================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.2750 605.675
------------ ----------
GBP15.2750 660.007
------------ ----------
GBP15.2750 563.370
------------ ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
1,829.052
GBP15.2750
=== ======================== ================================================
e) Date of the transaction 2017-10-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== =========================================================================
a) Name Mr B McNamara
=== ======================== ===============================================
b) Position/status CEO, GSK Consumer Healthcare
=== ======================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ===============================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 12 October 2017 on ADSs
held in the Company's 2009 Performance
Share Plan.
=== ======================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
$41.02 415.800
--------- ----------
$41.02 83.187
--------- ----------
$41.02 641.729
--------- ----------
$41.02 1,036.064
--------- ----------
=== ======================== ===============================================
d) Aggregated information
Aggregated volume
Price
2,176.780
$41.02
=== ======================== ===============================================
e) Date of the transaction 2017-10-12
=== ======================== ===============================================
f) Place of the n/a
transaction
=== ======================== ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr D S Redfern
=== ======================== ================================================
b) Position/status Chief Strategy Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.2750 993.680
------------ ----------
GBP15.2750 1,160.005
------------ ----------
GBP15.2750 1,094.561
------------ ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
3,248.246
GBP15.2750
=== ======================== ================================================
e) Date of the transaction 2017-10-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Ms C Thomas
=== ======================== ================================================
b) Position/status SVP, HR
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.2750 1,324.911
------------ ----------
GBP15.2750 1,460.009
------------ ----------
GBP15.2750 1,207.230
------------ ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
3,992.150
GBP15.2750
=== ======================== ================================================
e) Date of the transaction 2017-10-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ============================================================================
a) Name Mr P C Thomson
=== ========================== ================================================
b) Position/status President, Global Affairs
=== ======================== ==================================================
c) Initial notification/ Initial notification
amendment
=== ========================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ============================================================================
a) Name GlaxoSmithKline plc
=== ========================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ========================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ========================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ========================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.2750 766.560
------------ ----------
GBP15.2750 840.010
------------ ----------
GBP15.2750 756.529
------------ ----------
=== ========================== ================================================
d) Aggregated information
Aggregated volume
Price
2,363.099
GBP15.2750
=== ========================== ================================================
e) Date of the transaction 2017-10-12
=== ========================== ================================================
f) Place of the n/a
transaction
=== ========================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== =========================================================================
a) Name Mr D E Troy
=== ======================== ===============================================
b) Position/status SVP & General Counsel
=== ======================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ===============================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 12 October 2017 on ADSs
held in the Company's 2009 Performance
Share Plan.
=== ======================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
$41.02 1,132.956
--------- ----------
$41.02 1,314.438
--------- ----------
$41.02 1,154.472
--------- ----------
=== ======================== ===============================================
d) Aggregated information
Aggregated volume
Price
3,601.866
$41.02
=== ======================== ===============================================
e) Date of the transaction 2017-10-12
=== ======================== ===============================================
f) Place of the n/a
transaction
=== ======================== ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Dr P J T Vallance
=== ======================== ================================================
b) Position/status President, R&D
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.2750 2,755.819
------------ ----------
GBP15.2750 3,400.038
------------ ----------
GBP15.2750 3,138.824
------------ ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
9,294.681
GBP15.2750
=== ======================== ================================================
e) Date of the transaction 2017-10-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mrs V A Whyte
=== ======================== ================================================
b) Position/status Company Secretary
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP15.2750 169.685
------------ ----------
GBP15.2750 160.363
------------ ----------
GBP15.2750 150.569
------------ ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
480.617
GBP15.2750
=== ======================== ================================================
e) Date of the transaction 2017-10-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEQLFFDBFXFBX
(END) Dow Jones Newswires
October 16, 2017 11:40 ET (15:40 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024
